Pluvia's Fist.com - Pluvia's Plays & Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Pluvia's Fist.com - Pluvia's Plays & Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Valueman who wrote (984)	9/13/2000 8:37:07 AM
From: Pluvia	Read Replies (1) of 1766

Even a cursory examination of the two trials shows that the population of patients were significantly different in their level of previous exposure to ARVs, number of mutations, CD4 counts, etc. Your comparison of the two trials is flawed. 1. Once again you try to argue a point where you do not have facts to support your conclusion. 2. You have tried to use abstracts listed on the Trimeris website to support your position. 3. Unfortunately the abstracts are short on details. So short you cannot possibly know enough detail about the patient populations to make those statements. Furthermore, your point about the patient population does not address the fact that the Phase II trial design was flawed because it used two variables. Nor does it address the fact that T-20 cannot possibly be given all the credit for the positive results reported in the flawed Phase II trials. Once again, I suggest you speak with the PI's who ran the trials. The 4 we spoke to agree with our report's conclusion. Good Luck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next